melphalan
gsk
['fil,veral,12', 'melphalan', 'leukemia', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'manifest,(-manifest-2),(-manifest2),(-manifest 2),(-manifest-i),(-manifesti),(-manifest i)', 'leusm', 'novo ']
high-dose cytarabine and mitoxantrone before allo-hsct did not improve outcomes vs control in patients with relapsed/refractory #aml, according to the asap trial. presented at #ash22 by johannes schetelig. #leusm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.